• Member News

Horizon Discovery and Genewell Biotechnology enter into partnership for distribution of diagnostic reference standards for the Chinese market

Partnership immediately provides Horizon with deeper access to Chinese diagnostic assay manufacturers and potential OEM agreements as part of stated global leadership strategy.

Astex Continues to Deliver in Oncology as Erdafitinib, a Potential New Treatment for Metastatic Urothelial Cancer, Receives US FDA Breakthrough Therapy Designation

Astex Pharmaceuticals , a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its pharmaceutical collaborator, Janssen Pharmaceutica N.V. (Janssen), has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer.

Domainex appoints Dr Bodo Spori as Head of Business Development for Europe

Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.

NovaBiotics’ Lynovex receives Fast Track Designation for Cystic Fibrosis Exacerbations

NovaBiotics Ltd (NovaBiotics), a clinical-stage anti-infectives biotechnology company, announces receipt of Fast Track Designation (FTD) for its cystic fibrosis (CF) therapy, Lynovex®, from the United States Food and Drug Administration (FDA).

Congenica Achieves Global ISO 13485:2016 in vitro Diagnostic Device Quality Management Systems Certification

Congenica, a global provider of clinical genomics interpretation software, announced today that it has received certification in ISO 13485:2016, a quality management system for medical devices that supports comprehensive policies and processes across the entire business.

LifeArc announces £5M support for rare disease research

LifeArc®, the medical research charity, today announced its Philanthropic Fund will award £5M in grants to support medical research projects focused on rare diseases. The grants scheme was announced at the Drug Repurposing for Rare Diseases Conference 2018.

Prokarium secures $10 million investment from Saudi, Swedish and Korean investors for clinical development of revolutionary thermostable vaccines

Prokarium today announced the completion of a $10 million investment round. The round was led by Riyadh Valley Company, followed by Prokarium’s original investor Flerie Invest as well as Korea Investment Partners.

Congenica and SFI Research Centre FutureNeuro Unite to Deliver More Accurate Diagnoses for Genetic Epilepsy

New software to deliver faster and more accurate diagnoses in genetic epilepsies is the ambition of a ground-breaking partnership between Congenica, a global provider of clinical genomics interpretation software, and FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, supported by Science Foundation Ireland.

Horizon Discovery enters into license agreement with US immuno-oncology company

Horizon out-licenses proprietary cell line and Helitron transposon gene editing technologies, demonstrating Horizon’s ability to generate revenues from internally derived IP. Horizon retains commercial rights over improvements to its technology platforms to develop new cell line technologies and gene delivery IP that can be licensed to customers for applications in biomanufacturing, diagnostic reference standards, and cell therapy

Positive results achieved in ReViral's Phase IIa RSV challenge study

ReViral, a UK-based biotech company focused on developing novel compounds targeting respiratory syncytial virus (RSV), today announced successful results from its Phase IIa placebo-controlled challenge trial in healthy adult subjects infected intranasally with respiratory syncytial virus (RSV).